Skip to main content

Drug Interactions between doxorubicin liposomal and Zinecard

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dexrazoxane DOXOrubicin liposomal

Applies to: Zinecard (dexrazoxane) and doxorubicin liposomal

ADJUST DOSING INTERVAL: Coadministration with dexrazoxane may diminish the therapeutic response to doxorubicin. Since both are topoisomerase inhibitors, it is possible that dexrazoxane may interfere with the anti-tumor effects of doxorubicin. In a randomized clinical study of women with metastatic breast cancer, initiation of dexrazoxane with doxorubicin-based chemotherapy resulted in a significantly lower tumor response rate (48% vs. 63%) and shorter time to progression than doxorubicin-based chemotherapy plus placebo.

MANAGEMENT: When used as a cardioprotectant, dexrazoxane should not be administered at the initiation of doxorubicin-containing chemotherapy regimens. Dexrazoxane is indicated for reduction of the risk and severity of doxorubicin-induced cardiomyopathy in patients who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin.

References

  1. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn PROD (2001):
  2. "Product Information. Zinecard (dexrazoxane)." Pfizer U.S. Pharmaceuticals Group PROD (2001):
  3. Swain SM, Whaley FS, Gerber MC, et al. "Cardioprotection with dexrazoxane for doxorubicin- containing therapy in advanced breast cancer." J Clin Oncol 15 (1997): 1318-32
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
View all 4 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer